TPST Oct 2024 2.500 call
| Previous close | 1.7000 |
| Open | 1.7000 |
| Bid | 1.1000 |
| Ask | 1.7000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.7000 - 1.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 135 |
GlobeNewswireTempest to Participate in Upcoming Investor Conferences
BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that management will participate in the following upcoming investor conferences: TD Cowen's 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5,
- GlobeNewswire
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual MeetingPublished positive data from the Phase 1 Trial of TPST-1120 in patients with advanced solid tumors in the Journal of Cancer Research CommunicationsPresented new data at the SITC 2024 Spring Scientific Meeting elucidating the mechanism of TPST-1120 and supporting its potential in multiple cancers BRISBANE, Cali
- GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan. The stock options will vest over a four-year
